Rachel Roper

Prof. Rachel Roper

East Carolina University, Brody School of Medicine
orcid

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 May 2003 in Science
Verified
Journal Article
Closed access
PDF file
MMMarco A. Marra
Marco A. Marra
SJSteven J. M. Jones
Steven J. M. Jones
CACaroline R. Astell
Caroline R. Astell
RHRobert Holt
Robert Holt
ABAngela Brooks-Wilson
Angela Brooks-Wilson
Rachel RoperRachel Roper
Rachel Roper
We sequenced the 29,751-base genome of the severe acute respiratory syndrome (SARS)–associated coronavirus known as the Tor2 isolate. The genome sequence reveals that this coronavirus is only moderately related to other known coronaviruses, including two human coronaviruses, HCoV-OC43 and HCoV-229E. Phylogenetic analysis of the predicted viral proteins indicates that the virus does not closely resemble any of the three previously known groups of coronaviruses. The genome sequence will aid in the diagnosis of SARS virus infection in humans and potential animal hosts (using polymerase chain reaction and immunological tests), in the development of antivirals (including neutralizing antibodies), and in the identification of putative epitopes for vaccine development.

14 July 2005 in Virology
Verified
Journal Article
Closed access
NCNanhai Chen
Nanhai Chen
GLGuiyun Li
Guiyun Li
MLM. Kathryn Liszewski
M. Kathryn Liszewski
JAJohn P. Atkinson
John P. Atkinson
PJPeter B. Jahrling
Peter B. Jahrling
RBR. Mark L. Buller
R. Mark L. Buller

1 October 1991 in Immunology Today
Verified
Journal Article
Closed access
RPRichard P. Phipps
Richard P. Phipps
SSSidney H. Stein
Sidney H. Stein
Rachel RoperRachel Roper
Rachel Roper

1 August 1997 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
TSTsung‐Chang Sung
Tsung‐Chang Sung
Rachel RoperRachel Roper
Rachel Roper
YZYue Zhang
Yue Zhang
SRSimon A. Rudge
Simon A. Rudge
RTRyan Temel
Ryan Temel
MFMichael A. Frohman
Michael A. Frohman
Phospholipase D (PLD) genes are members of a superfamily that is defined by several highly conserved motifs. PLD in mammals has been proposed to play a role in membrane vesicular trafficking and signal transduction. Using site‐directed mutagenesis, 25 point mutants have been made in human PLD1 (hPLD1) and characterized. We find that a motif (HxKxxxxD) and a serine/threonine conserved in all members of the PLD superfamily are critical for PLD biochemical activity, suggesting a possible catalytic mechanism. Functional analysis of catalytically inactive point mutants for yeast PLD demonstrates that the meiotic phenotype ensuing from PLD deficiency in yeast derives from a loss of enzymatic activity. Finally, mutation of an HxKxxxxD motif found in a vaccinia viral protein expressed in the Golgi complex results in loss of efficient vaccinia virus cell‐to‐cell spreading, implicating the viral protein as a member of the superfamily and suggesting that it encodes a lipid modifying or binding activity. The results suggest that vaccinia virus and hPLD1 may act through analogous mechanisms to effect viral cellular egress and vesicular trafficking, respectively.

1 July 2003 in Journal of Virology
Verified
Journal Article
Closed access
CUChris Upton
Chris Upton
SSStephanie Slack
Stephanie Slack
AHArwen L. Hunter
Arwen L. Hunter
AEAngelika Ehlers
Angelika Ehlers
Rachel RoperRachel Roper
Rachel Roper
Increasingly complex bioinformatic analysis is necessitated by the plethora of sequence information currently available. A total of 21 poxvirus genomes have now been completely sequenced and annotated, and many more genomes will be available in the next few years. First, we describe the creation of a database of continuously corrected and updated genome sequences and an easy-to-use and extremely powerful suite of software tools for the analysis of genomes, genes, and proteins. These tools are available free to all researchers and, in most cases, alleviate the need for using multiple Internet sites for analysis. Further, we describe the use of these programs to identify conserved families of genes (poxvirus orthologous clusters) and have named the software suite POCs, which is available at www.poxvirus.org . Using POCs, we have identified a set of 49 absolutely conserved gene families—those which are conserved between the highly diverged families of insect-infecting entomopoxviruses and vertebrate-infecting chordopoxviruses. An additional set of 41 gene families conserved in chordopoxviruses was also identified. Thus, 90 genes are completely conserved in chordopoxviruses and comprise the minimum essential genome, and these will make excellent drug, antibody, vaccine, and detection targets. Finally, we describe the use of these tools to identify necessary annotation and sequencing updates in poxvirus genomes. For example, using POCs, we identified 19 genes that were widely conserved in poxviruses but missing from the vaccinia virus strain Tian Tan 1998 GenBank file. We have reannotated and resequenced fragments of this genome and verified that these genes are conserved in Tian Tan. The results for poxvirus genes and genomes are discussed in light of evolutionary processes.

1 July 2009 in Expert Review of Vaccines
Verified
Journal Article
Closed access
Rachel RoperRachel Roper
Rachel Roper
KRKristina E Rehm
Kristina E Rehm
In this review, the current state of vaccine development against human severe acute respiratory syndrome (SARS) coronavirus, focusing on recently published data is assessed. We discuss which strategies have been assessed immunologically and which have been evaluated in SARS coronavirus challenge models. We discuss inactivated vaccines, virally and bacterially vectored vaccines, recombinant protein and DNA vaccines, as well as the use of attenuated vaccines. Data regarding the correlates of protection, animal models and the available evidence regarding potential vaccine enhancement of SARS disease are discussed. While there is much evidence that various vaccine strategies against SARS are safe and immunogenic, vaccinated animals still display significant disease upon challenge. Current data suggest that intranasal vaccination may be crucial and that new or combination strategies may be required for good protective efficacy against SARS in humans.